CY1126136T1 - Μεθοδοι θεραπειας της αρθριτιδας - Google Patents
Μεθοδοι θεραπειας της αρθριτιδαςInfo
- Publication number
- CY1126136T1 CY1126136T1 CY20231100324T CY231100324T CY1126136T1 CY 1126136 T1 CY1126136 T1 CY 1126136T1 CY 20231100324 T CY20231100324 T CY 20231100324T CY 231100324 T CY231100324 T CY 231100324T CY 1126136 T1 CY1126136 T1 CY 1126136T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment methods
- arthritis treatment
- sustained release
- arthritis
- release composition
- Prior art date
Links
- 206010003246 arthritis Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 238000013268 sustained release Methods 0.000 abstract 2
- 239000012730 sustained-release form Substances 0.000 abstract 2
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Στο παρόν κείμενο περιλαμβάνονται μέθοδοι για την θεραπεία της αρθρίτιδας, οι οποίες περιλαμβάνουν τη χορήγηση μιας σύνθεσης παρατεταμένης αποδέσμευσης που περιέχει λιποσώματα τα οποία περιλαμβάνουν με τη σειρά τους ένα ή περισσότερα φωσφολιπίδια, χοληστερόλη, και έναν θεραπευτικό παράγοντα. Η σύνθεση παρατεταμένης αποδέσμευσης μπορεί να χορηγηθεί ενδοαρθρικά.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261668446P | 2012-07-05 | 2012-07-05 | |
US201361791650P | 2013-03-15 | 2013-03-15 | |
PCT/US2013/049442 WO2014008469A2 (en) | 2012-07-05 | 2013-07-05 | Methods of treating arthritis |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1126136T1 true CY1126136T1 (el) | 2023-11-15 |
Family
ID=49882628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20231100324T CY1126136T1 (el) | 2012-07-05 | 2023-07-10 | Μεθοδοι θεραπειας της αρθριτιδας |
Country Status (25)
Country | Link |
---|---|
US (5) | US9789062B2 (el) |
EP (1) | EP2854769B1 (el) |
JP (2) | JP6535281B2 (el) |
KR (2) | KR102176971B1 (el) |
CN (1) | CN105377238B (el) |
AU (1) | AU2013286575B2 (el) |
BR (1) | BR112015000174A2 (el) |
CA (1) | CA2878152C (el) |
CY (1) | CY1126136T1 (el) |
DK (1) | DK2854769T3 (el) |
ES (1) | ES2949093T3 (el) |
FI (1) | FI2854769T3 (el) |
HK (1) | HK1219414A1 (el) |
HR (1) | HRP20230655T1 (el) |
HU (1) | HUE062466T2 (el) |
LT (1) | LT2854769T (el) |
NZ (1) | NZ703532A (el) |
PL (1) | PL2854769T3 (el) |
PT (1) | PT2854769T (el) |
RU (1) | RU2677658C2 (el) |
SG (2) | SG10201610887WA (el) |
SI (1) | SI2854769T1 (el) |
TW (1) | TWI556838B (el) |
WO (1) | WO2014008469A2 (el) |
ZA (1) | ZA201500152B (el) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10610486B2 (en) | 2010-10-28 | 2020-04-07 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of a non-steroidal anti-inflammatory drug |
CA3025208A1 (en) * | 2016-05-24 | 2017-11-30 | Bol Pharma Ltd. | Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases |
ES2973248T3 (es) * | 2016-07-26 | 2024-06-19 | Inst Nat Sante Rech Med | Antagonista del receptor mineralocorticoide para el tratamiento de la osteoartritis |
CN107670020B (zh) * | 2016-08-02 | 2020-09-18 | 富比积生物科技股份有限公司 | 四胜肽gekg在治疗退化性关节炎中的用途 |
WO2018094253A1 (en) | 2016-11-18 | 2018-05-24 | Pacira Pharmaceuticals, Inc. | Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same |
RU2667467C1 (ru) * | 2017-05-17 | 2018-09-19 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Национальный исследовательский Мордовский государственный университет им. Н.П. Огарёва" | Липосомальный препарат дексаметазона в гипертоническом растворе хлорида натрия и способ лечения острого повреждения легких на его основе |
EP3651733A4 (en) * | 2017-07-10 | 2021-04-07 | ImmunoVaccine Technologies Inc. | PHARMACEUTICAL COMPOSITIONS, METHOD OF MANUFACTURING USING LIPID VESICLE PARTICLES OF DEFINED SIZE, AND USES THEREOF |
MY197149A (en) * | 2017-08-22 | 2023-05-26 | Moebius Medical Ltd | Liposomal formulation for joint lubrication |
JP7103726B2 (ja) * | 2017-11-09 | 2022-07-20 | イミューノヴァクシーン テクノロジーズ インコーポレイテッド | 医薬組成物、脂質ベシクル粒子の分粒を含む調製のための方法、及びそれらの使用 |
WO2020014118A1 (en) * | 2018-07-09 | 2020-01-16 | Taiwan Liposome Co., Ltd. | Methods to reduce complications of intra-articular steroid |
WO2020056399A1 (en) * | 2018-09-16 | 2020-03-19 | Tlc Biopharmaceuticals, Inc. | Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain |
JP7431419B2 (ja) * | 2018-11-14 | 2024-02-15 | タイワン リポソーム カンパニー リミテッド | 骨密度の低下または軟骨損失による疾患を治療するための治療剤を含む徐放性医薬組成物およびその使用 |
US11896713B2 (en) * | 2020-10-22 | 2024-02-13 | Rutgers, The State University Of New Jersey | Strategies to enhance lung cancer treatment |
CN112791063A (zh) * | 2021-01-19 | 2021-05-14 | 南通市中医院 | 一种用于清除关节腔积液中炎症因子及释放抗炎药物的载体 |
RU2762105C1 (ru) * | 2021-05-25 | 2021-12-15 | федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ оценки эффективности лечения псориатического артрита с помощью параметров антиоксидантной системы |
US20230098714A1 (en) * | 2021-08-06 | 2023-03-30 | New York R&D Center For Translational Medicine And Therapeutics, Inc. | Microrna compositions and methods of use |
WO2023172594A2 (en) * | 2022-03-08 | 2023-09-14 | Nova Southeastern University | Method for treating rheumatoid arthritis (ra) using an enzyme-and substrate selective exosite inhibitor of a disintegrin and metalloprotease 10 (adam10) |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ201010A (en) * | 1981-06-19 | 1986-02-21 | Ciba Geigy Ag | The treatment of inflammation diseases using desferrioxamine |
MX9203290A (es) * | 1983-09-19 | 1992-08-01 | Liposome Co Inc | Suministro localizado usando conjugados de fibronectina. |
US6759057B1 (en) | 1986-06-12 | 2004-07-06 | The Liposome Company, Inc. | Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs |
US6270766B1 (en) * | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
US5846217A (en) * | 1997-07-29 | 1998-12-08 | Iomed, Inc. | Iontophoretic bioelectrode and method of using same |
EP1406571A4 (en) * | 2001-06-25 | 2007-05-30 | Depuy Int Ltd | LIPOSOMAL ENCAPSULATION OF GLYCOSAMINOGLYCANS FOR THE TREATMENT OF ARTHROSIS JOINTS |
GB0118517D0 (en) | 2001-07-30 | 2001-09-19 | Mitsubishi Tokyo Pharm Inc | Compound |
EP1371362A1 (en) * | 2002-06-12 | 2003-12-17 | Universiteit Utrecht Holding B.V. | Composition for treatment of inflammatory disorders |
AU2004231362B2 (en) * | 2003-04-24 | 2009-11-12 | Jagotec Ag | Delayed release tablet with defined core geometry |
US10092662B2 (en) | 2004-03-31 | 2018-10-09 | University Of Utah Research Foundation | Macromolecular delivery systems for non-invasive imaging, evaluation and treatment of arthritis and other inflammatory diseases |
US20050260260A1 (en) * | 2004-05-19 | 2005-11-24 | Edward Kisak | Liposome compositions for the delivery of macromolecules |
US7744920B2 (en) | 2004-09-09 | 2010-06-29 | Hadasit Medical Research Services & Development Limited | Use of liposomal glucocorticoids for treating inflammatory states |
AU2006291429B2 (en) | 2005-09-15 | 2013-04-04 | Biontech Delivery Technologies Gmbh | Improvements in or relating to amphoteric liposomes |
PL3279663T3 (pl) * | 2006-03-15 | 2022-01-10 | The Brigham And Women's Hospital, Inc. | Zastosowanie gelsoliny do diagnozowania i leczenia chorób zapalnych |
DE602007007618D1 (de) | 2006-05-18 | 2010-08-19 | Univ Muenchen L Maximilians | Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis |
CN101512828B (zh) | 2006-07-06 | 2011-05-11 | 夏普株式会社 | 染料敏化型太阳能电池组件及其制备方法 |
WO2008030818A2 (en) | 2006-09-05 | 2008-03-13 | Mebiopharm Co., Ltd. | Novel liposome compositions |
ES2708851T3 (es) * | 2006-10-06 | 2019-04-11 | Bionet Pharma Gmbh | Un implante del núcleo pulposo espinal |
US8071127B2 (en) * | 2006-10-24 | 2011-12-06 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
US8956600B2 (en) * | 2009-08-10 | 2015-02-17 | Taiwan Liposome Co. Ltd. | Ophthalmic drug delivery system containing phospholipid and cholesterol |
US9770414B2 (en) | 2010-05-13 | 2017-09-26 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent |
CA2800693A1 (en) | 2010-05-28 | 2011-12-01 | Purdue Research Foundation | Delivery of therapeutic agents to inflamed tissues using folate-targeted agents |
US10610486B2 (en) | 2010-10-28 | 2020-04-07 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of a non-steroidal anti-inflammatory drug |
-
2013
- 2013-07-05 NZ NZ703532A patent/NZ703532A/en unknown
- 2013-07-05 JP JP2015520707A patent/JP6535281B2/ja active Active
- 2013-07-05 SG SG10201610887WA patent/SG10201610887WA/en unknown
- 2013-07-05 PT PT138132865T patent/PT2854769T/pt unknown
- 2013-07-05 LT LTEPPCT/US2013/049442T patent/LT2854769T/lt unknown
- 2013-07-05 AU AU2013286575A patent/AU2013286575B2/en active Active
- 2013-07-05 SI SI201332050T patent/SI2854769T1/sl unknown
- 2013-07-05 FI FIEP13813286.5T patent/FI2854769T3/fi active
- 2013-07-05 EP EP13813286.5A patent/EP2854769B1/en active Active
- 2013-07-05 BR BR112015000174A patent/BR112015000174A2/pt not_active Application Discontinuation
- 2013-07-05 SG SG11201408810TA patent/SG11201408810TA/en unknown
- 2013-07-05 CA CA2878152A patent/CA2878152C/en active Active
- 2013-07-05 US US14/411,530 patent/US9789062B2/en active Active
- 2013-07-05 WO PCT/US2013/049442 patent/WO2014008469A2/en active Application Filing
- 2013-07-05 CN CN201380035254.0A patent/CN105377238B/zh active Active
- 2013-07-05 HU HUE13813286A patent/HUE062466T2/hu unknown
- 2013-07-05 TW TW102124244A patent/TWI556838B/zh active
- 2013-07-05 KR KR1020157002869A patent/KR102176971B1/ko active IP Right Grant
- 2013-07-05 RU RU2015103538A patent/RU2677658C2/ru active
- 2013-07-05 DK DK13813286.5T patent/DK2854769T3/da active
- 2013-07-05 HR HRP20230655TT patent/HRP20230655T1/hr unknown
- 2013-07-05 KR KR1020207022150A patent/KR102302503B1/ko active IP Right Grant
- 2013-07-05 PL PL13813286.5T patent/PL2854769T3/pl unknown
- 2013-07-05 ES ES13813286T patent/ES2949093T3/es active Active
-
2015
- 2015-01-09 ZA ZA2015/00152A patent/ZA201500152B/en unknown
-
2016
- 2016-06-24 HK HK16107416.3A patent/HK1219414A1/zh unknown
-
2017
- 2017-09-05 US US15/695,649 patent/US10322086B2/en active Active
-
2018
- 2018-12-07 JP JP2018229873A patent/JP6964571B2/ja active Active
-
2019
- 2019-06-12 US US16/439,124 patent/US10736846B2/en active Active
-
2020
- 2020-05-15 US US16/875,167 patent/US10959951B2/en active Active
-
2021
- 2021-01-05 US US17/141,550 patent/US11793755B2/en active Active
-
2023
- 2023-07-10 CY CY20231100324T patent/CY1126136T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1126136T1 (el) | Μεθοδοι θεραπειας της αρθριτιδας | |
CY1124499T1 (el) | Λιπιδια για συστασεις διανομης θεραπευτικου παραγοντα | |
CY1121150T1 (el) | Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας | |
CY1121735T1 (el) | 7-benzyλ-10-(2-meθyλobenzyλ)-2,6,7,8,9,10-eξaϋδpoϊmiδazo[1,2-α]πυριδο[4,3-d]πυριμιδιν-5(3η)-ονη για χρηση στην αγωγη του καρκινου | |
CY1120832T1 (el) | Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων | |
CY1119960T1 (el) | Μεθοδοι για την αυξηση της αποτελεσματικοτητας της folr1 θεραπειας του καρκινου | |
CY1122624T1 (el) | Θεραπεια συνδυασμου του καρκινου | |
ECSP19078196A (es) | Composiciones terapéuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato | |
CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
PH12016500024A1 (en) | Bromodomain inhibitor | |
NI201000105A (es) | Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada. | |
CL2013003313A1 (es) | Compuestos derivados de 2,4-diaminoquinazolinas, sales o solvatos farmacéuticamente aceptables; composición farmacéutica que los comprende; y uso en el tratamiento de un trastorno en el que interviene la modulación de tlr7 y/o tlr8. | |
CY1122483T1 (el) | Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης | |
MX2021005317A (es) | Composiciones y métodos para absorción transmucosa. | |
MX2020010607A (es) | Compuestos y metodos para inhibir el transporte de fosfato. | |
EA201591363A1 (ru) | Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn | |
MX2014004862A (es) | Formulaciones de polimero acrilico. | |
CY1124331T1 (el) | Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης | |
CY1121628T1 (el) | 7-βενζυλ-4-(2-μεθυλοβενζυλ)-2,4,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(1η)-ονη, αλατα αυτης και μεθοδοι χρησης | |
CY1124512T1 (el) | Εμβολια καρκινου που στοχευουν καρκινικα βλαστοκυτταρα | |
BR112015014453A2 (pt) | produtos de cuidado oral compreendendo cloreto de zinco tetrabásico e trimetilglicina | |
GB201209587D0 (en) | Therapeutic compounds | |
CY1120133T1 (el) | Πυριδαζινονες ως αναστολεις ενζυμου daao | |
EP3229824A4 (en) | Oral octreotide administered in combination with other therapeutic agents | |
MX367926B (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. |